1025065-69-3

Basic information

• Product Name: SGI-1776
• Synonyms: SGI-1776;SGI-1776 free base;N-[(1-Methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-imidazo[1,2-b]pyridazin-6-amine;N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine;N-[(1-Methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-imidazo[1,2-b]pyridazin-6-amine SGI-1776;SGI-1776, >=98%;SGI-1776 free base N-[(1-Methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-imidazo[1,2-b]pyridazin-6-amine;N-[(1-Methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-imidazo[1,2-b]pyridazin-6-am
• CAS NO: 1025065-69-3
• Molecular Formula: C₂₀H₂₂F₃N₅O
• Molecular Weight: 405.4167896
• EINECS: 200-258-5
• Product Categories: Inhibitor;JAK/STAT;Inhibitors;JAK;STAT
• Mol File: 1025065-69-3.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.37
• Solubility: ≥40.5 mg/mL in DMSO; insoluble in H2O; ≥101 mg/mL in EtOH
• PKA: 9.22±0.10(Predicted)
• CAS DataBase Reference: SGI-1776(CAS DataBase Reference)
• NIST Chemistry Reference: SGI-1776(1025065-69-3)
• EPA Substance Registry System: SGI-1776(1025065-69-3)

Safety Data

• Hazardous Substances Data: 1025065-69-3(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 1025065-69-3 differently. You can refer to the following data:
1. A novel, ATP competitive inhibitor of Pim1, Pim2 and Pim3 with IC50s of 7 nM, 363 nM and 69 nM, respectively.
2. SGI-1776 is a Pim-1 kinase inhibitor. Potent PIM inhibitor.

Biological Activity

sgi-1776 free base, n-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent atp-competitive inhibitor of the serine/threonine family of pim kinase, an enzyme regulating cell survival. through extensive biomedical characterization, sgi-1776 exhibits specificity to the three isoforms of the pim family, including pim-1, pim-2, and pim-3. according to preliminary results from studies treating prostate cancer cells, sgi-1776 dose-dependently reduces phosphorylation of known pim kinase substrates involved in cell cycle progression and apotosis (p21cip1/waf1 and bad), compromises overall cell viability by inducing g1 cell cycle arrest and triggering apoptosis, and reduces cell viability in a multidrug resistance 1 (mdr1) protein based taxane-refractory prostate cancer cell line.shannon m. mumenthaler, patricia y.b. ng, amanda hodge, davide bearss, gregory berk, sarath kanekal, sanjeev redkar, pietro taverna, davide b. agus, and anjali jain. pharmacological inhibition of pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. mol cancer ther. 2009; 8(10): 2882-2893lisa s. chen, s anjeev redkar, david bearss, william g. wierda and varsha gandhi. pim kinase inhibitor, sgi-1776, induces apoptosis in cll lymphocytes. blood. 2009; 114(19): 4150-4157

Upstream product

• 7149-42-0 1-(1-methylpiperidin-4-yl)methanamine 
• 928337-00-2 6-chloro-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazine 

Relevant articles and documents

IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS

The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II), or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.